Norman Relkin

Dr. Norman Relkin is a practicing physician and neuroscientist specializing in age-related cognitive disorders. He is currently an Associate Professor of Neurology and Neuroscience at the Weill Cornell Medical College in New York and the Founding Director of its Memory Disorders Program. Dr Relkin attended the Harrow School in London, Yale College in Connecticut and the Medical Scientist Training Program (MD, PhD) at the Albert Einstein College of Medicine in New York. He completed Residency in Neurology and Fellowship in Behavioral Neurology and Neurophysiology at the New York Hospital – Cornell Medical Center. He is board certified in Neurology by the American Board of Psychiatry and Neurology. Over the past 25 years, Dr Relkin has authored over peer-reviewed 100 publications, including highly cited works on Alzheimer’s disease and other age-related neurodegenerative disorders. Dr Relkin was the principal author of the 2005 International Consensus Guidelines for NPH diagnosis and has contributed extensively to the clinical and basic science literature on this topic. He is holds several patents, including a CSF marker panel for AD diagnosis, a method for purification and quantifying anti-amyloid antibodies in blood and neuroimaging methods for differential diagnosis of dementia, Dr Relkin has been a principal investigator in over twenty Alzheimer clinical studies including two multicenter trials of his own design. Over the past decade, he pioneered the study of naturally occurring human antibodies for treatment of Alzheimer’s disease. He led all three phases of clinical studies of Intravenous Immunoglobulin as a potential treatment for Alzheimer’s disease, including the pivotal NIH and Baxter co-sponsored North American “GAP” study carried out at 45 sites in the US and Canada. Dr Relkin serves on the editorial boards of three scientific journals and is a peer reviewer for over a dozen others. He has served on NIH study sections and the scientific review boards for research funding agencies in Europe and Australia. He is a member of the ADCS, ADNI and the Adult Hydrocephalus Clinical Research Consortium. Since 2012, Dr Relkin has been an elected member the Board of Directors of The American Federation for Aging Research (AFAR).